Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose

Blood

Volumn 113, Issue 17, 2009, Pages 4125-4126

  Suarez Kurtz, Guilherme ^a   Perini, Jamila A ^a   Silva Assunção, Edimilson ^a   Struchiner, Claudio J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ANTICOAGULANT THERAPY; BRAZIL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE TITRATION; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; ENZYME SPECIFICITY; GENETICS; METABOLISM; NOTE;

ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; SUBSTRATE SPECIFICITY; WARFARIN;

EID: 65449178456     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2009-01-200600     Document Type: Letter

References (10)

1. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood. 2008;113:3925-3930.
2. Michaud V, Vanier MC, Brouillette D et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther. 2008;83:740-748. (Pubitemid 351556023)
3. Perini JA, Struchiner CJ, Silva-Assunção E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther. 2008;84:722-728.
4. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-2333.
5. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5:262-270. (Pubitemid 41131718)
6. Veenstra DL, You JH, Rieder MJ, et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics. 2005;15:687-691.
7. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006;79:291-302.
8. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006;16:101-110.
9. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331.
10. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753-764.